VTGN VistaGen Therapeutics, Inc.
Healthcare$0.65+0.00%OpenMarket Cap: $21.2M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.54
P/S
26.84
EV/EBITDA
0.36
DCF Value
$2.11
FCF Yield
-284.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
54.7%
Operating Margin
-8847.8%
Net Margin
-8486.8%
ROE
-109.7%
ROA
-103.1%
ROIC
-133.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 null | $303.0K | 37.6% | $-19.5M | $-18.9M | $— | — |
| Q2 null | $258.0K | 100.0% | $-20.1M | $-19.4M | $— | — |
| Q1 null | $244.0K | 30.7% | $-15.8M | $-15.1M | $— | — |
| Q4 null | $-15.0K | 100.0% | $-14.5M | $-13.6M | $— | — |
| FY null | $486.0K | 100.0% | $-56.0M | $-51.4M | $— | — |
| Q3 null | $234.0K | 100.0% | $-15.1M | $-14.1M | $— | — |
| Q2 null | $183.0K | 100.0% | $-14.2M | $-13.0M | $— | — |
| Q1 null | $84.0K | 100.0% | $-12.1M | $-10.7M | $— | — |
| Q4 null | $197.3K | 100.0% | $-11.4M | $-9.5M | $— | — |
| FY null | $1.1M | 100.0% | $-33.0M | $-29.4M | $— | — |
| Q3 2024 | $411.4K | 100.0% | $-7.9M | $-6.3M | $-0.43 | — |
| Q2 2024 | $278.0K | 100.0% | $-6.8M | $-6.6M | $-0.66 | — |